Co-Diagnostics, Inc. The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the District of Utah on behalf of shareholders of Co-Diagnostics, Inc. who purchased shares between February 25, 2020 and May 15, 2020.
The filed complaint alleges that Co-Diagnostics and its directors and officers (including PhD-level scientists who should know better) made continual, knowing, and willful misstatements about the Company’s main product, a Covid-19 diagnostic test. These misstatements had the effect of pumping up the price of Co-Diagnostics’ stock while Company officers and directors exercised low-priced options and dumped their stock into the market. Co-Diagnostics’ fraudulent misstatements displayed a disregard for basic scientific principles and caused investors to lose millions of dollars.
“Co-Diagnostics, Inc.”
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until August 17, 2020 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
